Australia’s medicines regulator close to decision on herceptin

	Tweet

Australia’s medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.

The recommendation is conditional on regular (no more than 12 monthly) updates on the results and data analyses of use of Herceptin.

The ADEC also recommended that the warnings in the Product Information (PI) document for all health professionals and the Consumer Medicine Information (CMI) document for patients be strengthened.

The application by Roche seeks to extend the use of Herceptin to include the treatment of women with early breast cancer who are HER2 positive and have undergone surgery and completed chemotherapy. At present Herceptin is only registered for use in advanced breast cancer.

The TGA will make the final decision as soon as matters, such as the amended product information, are agreed to by the company.

http://www.tga.gov.au/

RELATED STORIES:
Zoloft prescription unchanged!   Aspirin saves lives of cancer patients suffering heart attacks, despite fears of bleeding   Don’t compromise safety, says drug import report   New use for WD-40 lube spray - the war on drugs   New UTHealth Trial Aimed at Helping Pregnant Women Stop Smoking   Senators seek mandatory drug study database   Antibiotics sold illegally in Hispanic NYC stores   FDA says AstraZeneca Crestor ad is misleading   UK to rule Monday if Alzheimer’s drugs worth using   Vioxx increases heart attack risk in elderly   Pfizer Endometriosis Pain Drug Gets OK’d   Amgen’s Enbrel ad goes too far, US FDA says

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]